Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 91 Neoplasm Metastasis 24 Neoplasms 14 Brain Neoplasms 13 Prostatic Neoplasms 10 Endometrial Neoplasms 10 Carcinoma, Non-Small-Cell Lung 10 Ovarian Neoplasms 7 Glioblastoma 7 Glioma 6 Triple Negative Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Head and Neck Neoplasms 5 Colorectal Neoplasms 5 Sarcoma 4 Recurrence 4 Pancreatic Neoplasms 4 Lymphoma, Non-Hodgkin 4 Sarcoma, Ewing 3 Osteosarcoma 3 Neoplasms by Site 3 Multiple Myeloma 3 Meningioma 3 Melanoma 3 Carcinoma, Renal Cell 3 Breast Diseases 3 Unilateral Breast Neoplasms 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Oligodendroglioma 2

Interventions

Cyclophosphamide 31 Trastuzumab 30 Paclitaxel 28 Docetaxel 22 Taxes 18 Doxorubicin 18 Lapatinib 15 Radiotherapy 14 Capecitabine 14 Bevacizumab 13 Tamoxifen 12 Carboplatin 11 Filgrastim 9 sargramostim 8 Granulocyte-Macrophage Colony-Stimulating Factor 8 Chemotherapy, Adjuvant 8 exemestane 7 Vorinostat 7 Letrozole 7 Immunohistochemistry 7 Gemcitabine 7 Anastrozole 7 Albumin-Bound Paclitaxel 7 pegfilgrastim 6 Neoadjuvant Therapy 6 Magnetic Resonance Spectroscopy 6 Immunoenzyme Techniques 6 Goserelin 6 Flow Cytometry 6 Everolimus 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Neoplasms, Male × abemaciclib × Clear all

NCT05501704 2026-04-30

ETHAN - ET for Male BC

Dana-Farber Cancer Institute

Phase 2 Recruiting

Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon ⚡